Health ❯ Healthcare ❯ Obesity

Treatment Options

GLP-1 Medications Oral Medications Semaglutide GLP-1 Drugs Weight Loss Injections GLP-1 Agonists Tirzepatide Medication Mounjaro Pharmaceuticals Wegovy Medication Efficacy Injectable Medications Orforglipron GLP-1 Receptor Agonists Medications Weight Loss Medications Weight Management Weight Loss Jabs Patient Access Deprescription Strategies Injections GLP-1 Therapy Bariatric Surgery Prescription Medications Novo Nordisk Weight-Loss Injections NHS Availability Oral Therapies Injectable Drugs Medication Switching Clinical Pathways Medication Adherence NHS Access Inequality in Access Lifestyle Interventions FDA-Approved Medications Direct-to-Consumer Programs GLP-1 Therapies Amylin Analogs Wegovy Pill Medicare Coverage Medication Effects Microdosing Legitimate Sources for Medications Behavioral Programs Wegovy (semaglutide) Pill Form Biological Factors Semaglutide Approval Anti-Obesity Drugs Zepbound Chronic Disease Management Lifestyle Changes Hormonal Therapies Mounjaro and Ozempic Zepbound (tirzepatide) Weight Loss Surgery Incretin-based Therapies Pills vs Injections Amycretin Pills Surgical vs. Non-Surgical NHS Guidelines NHS Services Weight Loss Pills Injection Therapy Long-acting Medications Clinical Trials Surgical Interventions NHS Prescription NHS Prescribing Asthma Management Diet and Exercise

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Early prescription data show strong uptake driven by a needle‑free option with efficacy comparable to injections.

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Eli Lilly to Raise UK Mounjaro Prices by Up to 170% in September

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss